Gene Editing Ushers in a Revolution of "Large-Scale Rearrangement"! Bridge Recombinase: The "Magic Pen" Rewriting the Code of Life
Release time:
2025-11-17
If the human genome is compared to a "book of life" composed of 3 billion base pairs, traditional gene editing technologies are like meticulous proofreaders, capable only of correcting individual "typos." However, a groundbreaking study recently published in Science by the Arc Institute in the United States is propelling gene editing into the "era of large-scale rearrangement." The newly developed bridge recombinase technology allows scientists to reorganize chapters, flip paragraphs, and even rewrite entire pages of the genome as if wielding a "magic pen," opening new pathways for treating complex genetic diseases.
A Paradigm Shift from "Single-Letter Proofreading" to "Chapter Reconstruction"
Since the advent of the CRISPR-Cas9 system in 2012, this technology, which relies on guide RNA to locate and cut specific DNA sequences, has demonstrated immense value in areas such as genetic disease treatment and cancer immunotherapy. However, its essence remains making small-scale base edits by creating double-strand breaks. When faced with complex diseases like Friedreich's ataxia and certain neurodegenerative disorders—caused by large-scale gene duplications, deletions, or rearrangements—traditional tools reveal significant limitations: they are not only incapable of handling genomic regions spanning millions of base pairs but also struggle to safely achieve targeted modifications of chromosomal structures.
"It's like trying to revise a monumental book with scissors and glue, where current technologies can only cut and paste words, while we need to reorganize entire chapters," the research team leader analogized. The core of this breakthrough lies in the development of a bridge recombinase system with a "molecular bridge" function. Its innovative bridging RNA features two independent recognition modules that can simultaneously anchor two distant DNA sites, enabling precise excision, 180-degree inversion, or insertion of foreign sequences for large genomic fragments.
The "ISCro4" System Breaks Through Targeting Challenges
The research team screened the most efficient performer, ISCro4, from 72 natural recombinase systems and, through thousands of directed evolution experiments, achieved 82% targeting specificity in human cells. This enzyme system not only efficiently handles ultra-long repetitive sequences (such as the abnormally expanded GAA repeats in Friedreich's ataxia) that are beyond the reach of traditional technologies but can also simulate complex mutation processes like chromosomal translocations. Experimental data show that the technology successfully excised over 80% of pathogenic GAA repeats in patient cells, significantly improving disease model phenotypes.
Even more promising is that bridge recombinase requires only the delivery of RNA molecules to function, avoiding the complex protein carrier delivery challenges associated with CRISPR technology and substantially reducing treatment risks. The research team has verified its compatibility with existing therapeutic models, such as sickle cell anemia, and is now developing enhanced versions suitable for stem cells and immune cells, aiming to achieve precise manipulation of even larger gene fragments (exceeding 500 kb).
Opening a New Era of Precision Medicine
Experts in the field note that this breakthrough marks the transition of gene editing from the "molecular scissors" era to the "genetic architect" phase. Beyond genetic disease treatment, the technology shows broad prospects in cancer genome remodeling, agricultural crop trait improvement, and synthetic biology. As highlighted in a commentary accompanying the Science publication, "When scientists gain the ability to reorganize the blueprint of life, we stand at the tipping point of a biomedical revolution."
With the continuous optimization of bridge recombinase technology, humanity may be just one precise "gene rearrangement" away from conquering many currently incurable diseases.
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
